In this article, we break down the 5 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market. For investors looking for the complete list, you can explore our full report on the 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market.
5. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) takes fifth place because it is attacking two of the weight-loss market’s next major questions: how to deliver powerful obesity treatment and how to prevent patients from losing too much lean muscle. The company’s growing metabolic portfolio now includes olatorepatide, a GLP-1 and GIP receptor agonist licensed for global development, as well as trevogrumab, an antibody designed to block myostatin and help preserve muscle during pharmacological weight loss.
In March 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that olatorepatide had produced body-weight loss of as much as 19% at 48 weeks in a Phase 3 trial conducted in Chinese patients. Regeneron planned to begin a global Phase 3 registration program later in 2026. That asset gives the company a potential stand-alone obesity drug rather than leaving it dependent solely on combinations with a competitor’s GLP-1 medicine.
The Phase 2 COURAGE study provides the more differentiated element of the story. When trevogrumab was combined with semaglutide, the regimen prevented approximately half of the lean-mass loss associated with semaglutide while increasing fat-mass reduction. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) continued presenting muscle and body-composition research during 2026. Muscle-preserving obesity treatments could eventually become a market worth more than $30 billion by 2035, according to an estimate cited by Reuters, particularly for older patients and others vulnerable to weakness or functional decline.
Click next to see the following stock...
